"The committee selected Celgene for its high growth potential of cancer-treatment drugs in coming years coupled with a reasonable valuation," said Adam Ritt, editor of BetterInvesting Magazine. "For the Undervalued selection, the committee cited as catalysts Amgen's phase three trails for cholesterol and migraine drugs and the cessation of a royalty payment to Pfizer in October."
Check BetterInvesting's October issue for more details about these selections. Go to the trial version of BetterInvesting's online tools to study the investment potential of Celgene and Amgen by viewing their fundamental data and applying judgments.
Committee members are Kenneth M. Bernard, CFA; Robert M. Bilkie, Jr., CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip S. Dano, CFA; Donald E. Danko, CFA; Maury Elvekrog, CFA; and Walter J. Kirchberger, CFA.
As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors and are not intended as investment recommendations. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.
BetterInvesting is a national nonprofit organization that has been empowering individual investors since 1951. Founded in Detroit, the association (formerly known as National Association of Investors Corporation) was borne out of the conviction that anyone can become a successful long-term investor by following commonsense investing practices. BetterInvesting has helped more than 5 million people become better, more informed investors by providing webinars, in-person events, easy-to-use online tools for analyzing stocks, a monthly magazine and a community of volunteers and like-minded investors. For more information about BetterInvesting, visit its website at www.betterinvesting.org or call toll free (877) 275-6242.
Follow us on Twitter and Facebook.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/betterinvesting-magazine-releases-october-stock-to-study-and-undervalued-stock-choices-for-investors-informational-and-educational-use-300310012.html